AKT1 and alveolar rhabdomyosarcoma: Accordingly, NF-κB inhibitors—alone or in combination with AKT and/or cdk4 inhibitors—have been proposed to restore differentiation capacity and enhance chemotherapy efficacy in ARMS [118].